---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-180830"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:28:26.848386+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# IO Biotech Q2 net loss $26.2M; Ph3 Cylembio trial misses PFS endpoint, plans FDA meeting fall 2025

## Summary
- Phase 3 trial of Cylembio+Keytruda in advanced melanoma showed clinical improvement in PFS but narrowly missed statistical significance.
- Company plans to meet with FDA in fall 2025 to discuss data and potential BLA submission for Cylembio.
- Net loss of $26.2M for Q2 2025 vs $20.7M in Q2 2024; R&D expenses $16.7M, G&A $6.5M.
- Cash and equivalents $28.1M at June 30, 2025; plus €12.5M EIB loan received July 4, funding into Q1 2026.
- Upcoming investor conferences: Morgan Stanley (Sept 9) and H.C. Wainwright (Sept 10) with management presentations.

## SEC filing metadata
- accession: 0001193125-25-180830
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312525180830/0001193125-25-180830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312525180830/d34608d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-180830
- JSON: https://secwatch.observer/filing/0001193125-25-180830.json
- Plain text: https://secwatch.observer/filing/0001193125-25-180830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.